Alonso Villasmil Ocando

Rodin Therapeutics (United States) — United States

Medicine · Health Sciences

4h-index48citations16works0.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(9), Immunotherapy and Immune Responses(6), HIV Research and Treatment(4), Cancer Immunotherapy and Biomarkers(4), Monoclonal and Polyclonal Antibodies Research(3)

Publications16 total

Potent cytotoxic tumor-infiltrating lymphocytes can be generated from immune-excluded chondrosarcomas using regulatable membrane-bound IL15
Cancer Immunology Research·2026Open Access
Abstract LB359: OBX-115 TIL from non-small cell lung cancer (NSCLC) are enriched for putative tumor-reactive, stem-like T cells with enhanced tumor cytotoxicity: Results from multimodal phenotyping analysis
Cancer Research·2025
IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15
Molecular Therapy·2025· 5 citedOpen Access
Abstract B001: Effective generation of potent tumor-infiltrating lymphocytes (TIL) expressing regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) from immune-excluded chondrosarcoma
Cancer Immunology Research·2025
463 Antigen-responsive promoters coupled with cytoDRiVE<sup>®</sup> technology provide tight spatiotemporal regulation for tumor-infiltrating lymphocytes (TIL) expressing membrane-bound IL12
Regular and Young Investigator Award Abstracts·2024Open Access
444 Potential feasibility of core needle biopsy tumor tissue procurement method for TIL cell therapy with OBX-115 in non-small cell lung cancer (NSCLC)
Regular and Young Investigator Award Abstracts·2024Open Access
348 TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence in the presence of TAA
Regular and Young Investigator Award Abstracts·2023Open Access
On a path toward a broad-spectrum anti-viral: inhibition of HIV-1 and coronavirus replication by SR kinase inhibitor harmine
Journal of Virology·2023· 15 citedOpen Access
Abstract LB096: IL15-engineered tumor infiltrating lymphocytes (cytoTIL15TM) exhibit activity against autologous tumor cells from multiple solid tumor indications without IL2
Cancer Research·2023· 4 cited
390 Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15® therapy) in an allogeneic melanoma PDX model
Regular and Young Investigator Award Abstracts·2022Open Access
Opposing roles of CLK SR kinases in controlling HIV-1 gene expression and latency
Retrovirology·2022· 16 citedOpen Access
Abstract LB212: Allogeneic, IL-2-independent tumor-infiltrating lymphocytes expressing membrane-bound IL-15 (cytoTIL15) eradicate tumors in a melanoma PDX model through recognition of shared tumor antigens
Cancer Research·2022· 2 cited
166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo
Regular and Young Investigator Award Abstracts·2021· 5 citedOpen Access
1008P cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety &amp; efficacy and expand patient eligibility
Annals of Oncology·2021· 1 cited
HIV-infected macrophages evade NK cell-mediated killing while driving inflammation
The Journal of Immunology·2020
HIV-infected macrophages evade NK cell-mediated killing while driving inflammation
Journal of Virus Eradication·2019Open Access

Frequent Co-authors

Michelle Ols(12), Jan ter Meulen(12), Rachel A. Burga(10), Jeremy H. Tchaicha(8), Dhruv K. Sethi(7), Kyle D. Pedro(7), Benjamin Primack(7), Theresa Ross(7), Gauri Kulkarni(6), Bülent Arman Aksoy(5), Scott Lajoie(5), Meghan Langley(5), Zheng Ao(5), Kiera Clayton(4), Dexue Sun(4), Violet Young(4), Zheng Ao(3), Mithun Khattar(3), Jack Tremblay(3), Gwen Wilmes(3)